The oral drug, amcenestrant, was tested with Pfizer’s approved breast cancer drug palbociclib, but the combination didn’t “meet the prespecified boundary for continuation,” according to an Aug. 17 press release.
Physicians will transition the study participants who took the combination to receiving other treatments or palbociclib and letrozole, another breast cancer drug.
The company said it would share the data in the future.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
